Evidence map›Paper›PMID 25743373›Full record

ArticleArchives of toxicology2016

Resolving pathways of interaction of mipafox and a sarin analog with human acetylcholinesterase by kinetics, mass spectrometry and molecular modeling approaches.

I Mangas, P Taylor, E Vilanova, J Estévez, T C C França, E Komives, Z Radić

Open access · greenAbstract read
In one paragraph

Article in Archives of toxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

I MangasUnit of Toxicology and Chemical Safety, Institute of Bioengineering, University Miguel Hernandez of Elche, Alicante, Spain. imangas@umh.es.
P TaylorDepartment of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, 92093, USA.
E VilanovaUnit of Toxicology and Chemical Safety, Institute of Bioengineering, University Miguel Hernandez of Elche, Alicante, Spain.
J EstévezUnit of Toxicology and Chemical Safety, Institute of Bioengineering, University Miguel Hernandez of Elche, Alicante, Spain.
T C C FrançaLaboratory of Molecular Modeling Applied to the Chemical and Biological Defense, Military Institute of Engineering, Rio de Janeiro, Brazil.
E KomivesDepartment of Chemistry-Biochemistry, University of California San Diego, La Jolla, CA, 92093, USA.
Z RadićDepartment of Pharmacology, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, 92093, USA.
Universitat de Miguel Hernández d'Elx · ESUniversity of Montana · USMilitary Institute of Engineering · BRUniversity of California, San Diego · US

Funding

KINETICS OF DRUG MACROMOLECULE COMPLEX FORMATIONR37GM018360 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TAYLOR, PALMER WILLIAM · 1999 to 2008
$5.7M
KINETICS OF DRUG-MACROMOLECULE COMPLEX FORMATIONR01GM018360 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TAYLOR, PALMER WILLIAM · 1985 to 2013
$2.8M
NIGMS NIH HHS GM1836036NIGMS NIH HHS R01 GM018360NIGMS NIH HHS R37 GM018360
6 · The paper itself

Abstract

The hydroxyl oxygen of the catalytic triad serine in the active center of serine hydrolase acetylcholinesterase (AChE) attacks organophosphorus compounds (OPs) at the phosphorus atom to displace the primary leaving group and to form a covalent bond. Inhibited AChE can be reactivated by cleavage of the Ser-phosphorus bond either spontaneously or through a reaction with nucleophilic agents, such as oximes. At the same time, the inhibited AChE adduct can lose part of the molecule by progressive dealkylation over time in a process called aging. Reactivation of the aged enzyme has not yet been demonstrated. Here, our goal was to study oxime reactivation and aging reactions of human AChE inhibited by mipafox or a sarin analog (Flu-MPs, fluorescent methylphosphonate). Progressive reactivation was observed after Flu-MPs inhibition using oxime 2-PAM. However, no reactivation was observed after mipafox inhibition with 2-PAM or the more potent oximes used. A peptide fingerprinted mass spectrometry (MS) method, which clearly distinguished the peptide with the active serine (active center peptide, ACP) of the human AChE adducted with OPs, was developed by MALDI-TOF and MALDI-TOF/TOF. The ACP was detected with a diethyl-phosphorylated adduct after paraoxon inhibition, and with an isopropylmethyl-phosphonylated and a methyl-phosphonylated adduct after Flu-MPs inhibition and subsequent aging. Nevertheless, nonaged nonreactivated complexes were seen after mipafox inhibition and incubation with oximes, where MS data showed an ACP with an NN diisopropyl phosphoryl adduct. The kinetic experiments showed no reactivation of activity. The computational molecular model analysis of the mipafox-inhibited hAChE plots of energy versus distance between the atoms separated by dealkylation showed a high energy demand, thus little aging probability. However, with Flu-MPs and DFP, where aging was observed in our MS data and in previously published crystal structures, the energy demand calculated in modeling was lower and, consequently, aging appeared as a more likely reaction. We document here direct evidence for a phosphorylated hAChE refractory to oxime reactivation, although we observed no aging.

Indexed as

AcetylcholinesteraseAmino Acid SequenceCatalytic DomainCholinesterase InhibitorsCholinesterase ReactivatorsHumansIsoflurophateKineticsModels, MolecularMolecular Sequence DataOrganophosphorus CompoundsOximesParaoxonPhosphorylationProtein ConformationSarinAcetylcholinesteraseCholinesterase InhibitorsCholinesterase ReactivatorsIsoflurophatemethylphosphonic acidmipafoxOrganophosphorus CompoundsOximesParaoxonSarinSerineAcetylcholinesteraseAgingMipafoxOrganophosphorus compoundsOximesSarin

Identifiers

PMID25743373
PMCPMC4833118
OpenAlexW2058472605

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.